AzTrials
AzTrials

Stable AnginaNANOM-FIMNCT01270139

Plasmonic Nanophotothermal Therapy of Atherosclerosis

A study testing Transplantation of nanoparticles, Transplantation of iron-bearing nanoparticles and Stenting in people with Stable Angina and Heart Failure, run by Ural State Medical University at 4 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigators hypothesize that the nanoburning is a very challenging technique to demolish and reverse the plaque especially in combination with stem cell technologies promising the functional restoration of the vessel wall. Read more about this study

Who is it for?
Ages 45 to 65 years
Conditions the study is for
Stable Angina, Heart Failure, Atherosclerosis
What is being tested?
Transplantation of nanoparticles, Transplantation of iron-bearing nanoparticles and Stenting
Could I receive a placebo?
No, everyone receives an active treatment
How many people
180 participants
Where
4 sitesin 2 countries
Study dates
1 Apr 2007to 1 Aug 2016
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 45 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • age 45-65 years old
  • male and female
  • single- or multi-vessel CAD with flow-limiting lesions
  • no indications for coronary artery bypass surgery (CABG)
  • stable angina with indications for percutaneous coronary interventions (PCI)
  • NYHA (New York Heart Association) I-III functional class of heart failure (HF)
  • treated hypertension (in supine position: systole >140 mm Hg, diastole >90 mm Hg)
  • de novo treated.

Who cannot join

  • non-compliance,
  • angiographic SYNTAX score ≥23
  • history of myocardial infarction (MI), unstable angina, PCI or CABG, atrial fibrillation or other dysrhythmias, stroke
  • presence of indications for CABG
  • presence of contraindications for PCI or CABG
  • NYHA IV functional class of HF
Show all 12Show fewer
  • diabetes mellitus (in case of fasting glucose >7.0 mM/L or random glucose >11.0 mM/L)
  • untreated hypertension
  • asthma
  • known hypersensitivity or contraindications to anti-platelet drugs
  • contrast sensitivity
  • participation to any drug- or intervention-investigation during the previous 60 days

Trial locations and contacts

4 sites in 2 countries.

4 sites in 2 countries

Russia3 sites
  • Ural Center of Modern Nanotechnologies, Institute of Natural Sciences, Ural Federal University

    Yekaterinburg, Sverdlovsk Oblast, 620000

  • Transfiguration Clinic

    Yekaterinburg, Sverdlovsk Oblast, 620078

  • Ural Institute of Cardiology

    Yekaterinburg, Sverdlovsk Oblast, 620144

Other trials in Russia

Netherlands1 site
  • De Haar Research Task Force

    Amsterdam, North Holland, 1069CD

Other trials in Netherlands

About this study

Official title: Plasmonic Photothermal Therapy of Flow-Limiting Atherosclerotic Lesions With Silica-Gold Nanoparticles: a First-in-Man Study

The investigators hypothesize that the nanoburning is a very challenging technique to demolish and reverse the plaque especially in combination with stem cell technologies promising the functional restoration of the vessel wall.

The completed (in July 2012) interventional three arms (n=180) first-in-man trial (the NANOM-FIM trial) assessed (NCT01270139) the safety and feasibility of two delivery techniques for nanoparticles (NP), and plasmonic photothermal therapy (PPTT) of atherosclerotic lesions. Patients were assigned in a 1:1:1 ratio to receive either (1) nano-intervention with delivery of silica-gold NP in mini-surgery implanted bioengineered on-artery patch (n=60), or (2) nano-intervention with delivery of silica-gold iron-bearing NP with targeted micro-bubbles or stem cells in hands of magnetic navigation system (n=60) versus (3) stent implantation (n=60). The primary outcome was TAV at 12 months.

Read more

The observational prospective cohort analysis (an amendment to the protocol of August 29th 2012 with a decision to extend a 1-year study for another 4 years with the assessment of the 5-year clinical outcomes both retro- and prospectively) of the long-term clinical outcomes at the intention-to-treat population of 180 patients with CAD and angiographic SYNTAX score ≤22 enrolled initially to NANOM-FIM trial will be performed at 5 years after the intervention. The primary outcome will be a MACE-free survival. The secondary outcomes will be MACE, cardiac death, TLR (target lesion revascularization) and TVR (target vessel revascularization). Imaging endpoints will be assessed pre-, post- procedure and at 12-month follow-up. Clinical endpoints will be analyzed at the baseline and at 12 and 60-month follow-up (the release of results is expected after October 2016). Parameters of nanotoxicity will be assessed. The independent adjudication analysis of the clinical outcomes is scheduled in 2017-2019.

The subset post-hoc analysis will be conducted at 1- and 5-year follow-up (by the Amendment of August 29th 2012). At the first subset, patients underwent stenting with XIENCE V stent proximal to the site of nano-intervention (n=13). Subjects in the second subset were undergone drug-coated balloon pre-dilation with further nano-technique (n=20). Lesions in patients of the third subset were not prepared for the nano-approach (n=147) (neither stenting nor balloon angioplasty). The analysis will be performed and results will be released after 2018 with the same clinical outcomes.

This project and related manuscripts were not prepared or funded in any part by a commercial organization. Nanoparticles and biomedical equipment were supplied free for the study by the non-profit Agiko and De Haar Research Task Force (Rotterdam-Amsterdam, the Netherlands). All rights of the authors are reserved. The access of the international academic or governmental organizations to the essential and primary data of the trial is restricted by the Russian governmental authorities due to the interest of the Russian Federal Security Service (FSB).

Read the detailed description

Cardiovascular disease (CVD) is one of the main cause of disability and death worldwide. The underlying cause generally is atherosclerosis and more in particular thrombotic rupture of an atherosclerotic plaque in a vital artery. The restoration of blood flow to ischemic myocardium is established as the preeminent objective for the treatment of patients with CVD. Some modern angioplasty techniques generally just manipulate the form of the plaque and have some clinical and technical restrictions, relatively high complication rate and restenosis risk.

The most common techniques in current practice are angioplasty with stenting, and CABG surgery (for patients with multivessel disease). Balloon angioplasty and stenting, in fact, manage the form of the plaque and does not create a significant problem of plaque residue flowing from the site. Once a role for elective stent implantation was established, the next goal was to overcome the complications of subacute stent thrombosis (first of all, with the use of drug-eluting stents) and neointimal hyperplasia (bare-metal stents) through pharmacologic and physical means. Among unresolved issues, the investigators can describe restrictions in patients with stenosis of an unprotected left main coronary artery, multivessel disease, diabetes mellitus, still rather high rate of in-stent restenosis, and as a solution of the problem with a foreign body in a vessel, the development of biodegradable stents. Among physical obstacles for stenting, the investigators may note that atherosclerotic plaque build-up can exist in a number of different forms. The plaque can be quite hard and scaly, or more fatty and pliable. Moreover, Dr Peters D. with colleagues from Santa-Barbara (2009) published own data about new modular, multifunctional micelles that contain a targeting element, a fluorophore, and, when desired, a drug component in the same particle. Targeting atherosclerotic plaques in ApoE-KO mice fed a high-fat diet was accomplished with the pentapeptide cysteine-arginine-glutamic acid-lysine-alanine, which binds to clotted plasma proteins. The fluorescent micelles bind to the entire surface of the plaque, and notably, concentrate at the shoulders of the plaque, a location that is prone to rupture. They also show that the targeted micelles deliver an increased concentration of the anticoagulant drug hirulog to the plaque compared with untargeted micelles that may reduce bleeding complications and atherogenesis.

Moreover, the ability of statin drugs to reduce the volume of atherosclerotic plaque in the coronary artery wall, termed plaque regression, has received much attention. The statins have a remarkable track record of lowering cholesterol and improving survival. Apart from lowering low-density lipoprotein cholesterol (LDL-C) levels, they also have a multitude of other actions, often collectively described as pleiotropic effects. JUPITER (2003), REVERSAL (2004), PROVE IT (2004), ESTABLISH (2004), and ASTEROID (2006) trials have shown that low LDL levels after intensive statin therapy when accompanied by raised HDL, can regress, or partially reverse, the plaque buildup in the coronary arteries. The findings suggest that the various components of atheroma respond differently to treatment with medical therapies, and can be used to target plaques that are likely to respond. Thus, lipid pool, inflammatory reaction in the forms of cellular migration, humoral substance release, and oedema are still the most likely to be targets of pharmacotherapy. But, for instance, fibrous tissue, mineral deposits, and ground substance would seem to be irreversible despite metabolic manipulation.

Numerous devices recently have been described that utilize the application of heat to resolve atherosclerotic plaque (laser technique, electrosurgical removing of plaque, or with the use of radio frequency sparking, and others). Plasmonics is a novel invasive approach in medicine, and metal nanoparticles are a new type of optically active composite spherical one consisting of a dielectric core covered by a thin metallic shell which is typically gold. When nanoparticles are irradiated with a near-infrared laser, they absorb energy, which is quickly transferred through nonradiative relaxation into heat and accompanying effects, and eventually leads to irreparable damage of tissue. In oncology, metal nanoparticles may provide a novel means of targeted plasmonic photothermal therapy (PPTT) in tumour tissue, minimizing damage to surrounding healthy tissue. However, this approach does not use in cardiology today possessing the great potential for angioplasty. The efficiency of nanotechnologies, however, is limited by gaps in the current understanding of the thermal interactions between nanoparticles and laser light pulses or continuous waves in the context of complex biological environments. Irradiation, even with moderate pulses of energy, can induce melting, evaporation, and fragmentation of nanoparticles. These events can drastically alter the intended therapeutic effects and lead to the formation of vapour bubbles as well as acoustic waves and shock waves. But the last disadvantages can become advantages depending on the purposes of the treatment. Thus the study opens a new chapter in the history of plasmonics.

The investigators designed this study to check potent clinical opportunities, efficacy and safety of such a novel technique for angioplasty as plasmonic atherodestruction. The investigators have drawn the following research questions: 1) Is it possible to plasmonically entirely destruct a plaque with minimal complications? 2) What level of safety is typical for the different approaches if compare with stenting? 3) What are the advantages and disadvantages of the different delivery techniques - stem cells or magnetic field? 4) What is the meaning of the transplanted mesenchymal CD73+CD105+ stem-progenitor cells for atherosclerosis management? 5) Can plasmonic nanophotothermal therapy (PPTT) get an alternative to stenting?

Plasmonic photothermal therapy (PPTT) can potentially reduce the volume of plaque. PPTT melts an atherosclerotic plaque tissue with irreparable burning of targeted tissues, vapour bubbling of cellular cytoplasm and extracellular matrix with subsequent degradation of tissues, and destructive effects of acoustic and shock waves as the possible plaque-killing mechanisms. NPs are absolutely safe for an organism but entire kinetics is mostly unknown. The most dangerous approach with the lowest level of efficacy and safety is delivery of NPs with microbubbles if compare with stem cell-based one. Mesenchymal stem cells have appropriate effectiveness as a local delivery system with a lot of beneficial properties such as anti-inflammatory, anti-apoptotic, and multi-metabolic effects leading to plaque degradation. Thus, PPTT can become an alternative to stenting.

Among potential problems the investigators may name 1) technique of the delivery of these nanoparticles directly into the plaque (stem cells, aleuronic microbubbles with surfaced antibodies (as a local delivery system), direct injection or infusion into the coronary arteries and plaques during CABG or PCI); 2) high risk of acute fatal atherothrombosis at the heat site due to destruction of the fibrous cap of plaque (role of nanoparticles adhesion on the surface of endothelium); 3) long-term effects of the nanodestruction locally and in entire organism (distribution and effects of accumulation in different organs); 4) mechanism of this effect (plasmonic microexplosion and burning of tissue, lysis of cells due to vapor bubbling of cellular cytoplasm and extracellular tissues, destructive acoustic and shock waves); 5) optimal biophysical parameters and necessary energy levels of nanodetonation to prevent burning of surrounding tissues and perforation of the vessel; 6) plasmonic damage is irreparable, and it means the investigators have to combine it with another biotechnology for the restoration of vessel such as the use of stem cells; 7) optimal type of stem cells (source, origin, level of differentiation, potential, properties).

So, disadvantages of current low-invasive approaches (stenting, statin drugs, and others, laser, electrosurgery devices):

  • Foreign body in the heart
  • Restenosis, including neointimal hyperplasia (adventitial and circulating stem-progenitor cells of different origin are involved)
  • Risk of fatal acute or sub-acute atherothrombosis (including 'in-stent' sub-acute atherothrombosis)
  • Non-pathogenetic - cannot reverse or significantly regress the plaque
  • No effect for remodeling and calcification (restriction for necessary remodeling)
  • Clinical restrictions for some group (multivessel disease, left main CAD, diabetes mellitus, severe CAD and etc), on another hand, CABG is a very traumatic procedure (solution - MICS, including achievements in endoscopic stereotaxic surgery), but CABG is still an approach in charge in severe or high-risk patients

Disadvantages of the studied approach:

  • The necessity of the special delivery technique
  • The lost function of the artery - irreparable pro-fibrotic damage - the necessity of another clinical management for restoration of tissue - the necessity of the restoration therapy with stem cells
  • The threat of acute fatal atherothrombosis due to rupture of (vulnerable) plaque
  • Cannot treat non-organic part of plaque - the necessity of the special therapy - stem cells
  • The harm of potent detrimental side-effects - vapour bubbling (boiling of cytoplasm and ECM with subsequent lysis of cells, and provocation of pro-apoptotic cascades), acoustic and shock waves due to the plasma-generated laser-related detonation of nanoshells in tissue
  • Erratic (uncontrollable) heating - surrounding tissue of the site of interest can achieve a temperature until 38-39°. But at the site of burning final temperature can be at about 50-180 C (cauterization/ searing/ melting effect) with following the pro-fibrous effect of tissue.
Being tested
Transplantation of nanoparticles, Transplantation of iron-bearing nanoparticles, Stenting
Keywords
nanoparticles, mesenchymal stem cell, plasmonics, atherosclerosis, IVUS, stenting
Medical subject headings
Angina, Stable, Heart Failure, Atherosclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transplantation of nanoparticlesProcedure or surgery

    60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells

  • Transplantation of iron-bearing nanoparticlesProcedure or surgery

    60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system

  • StentingDevice

    Also called XIENCE V

    60 - in sirolimus-eluting stenting control

Study groups in NCT01270139
Study groupRoleWhat they receive
Nano groupExperimental60 patients in Nano group were treated with transplantation of nanoparticles (NP), particularly with a bioengineered patch that was grown with allogenous stem cells pre-cultivated in the medium with NP. After the admission, patients were examined with QCA, and allocated to the trial. The implantation of the patch onto the artery was undergone by the minimally invasive cardiac surgery (MICS CABG) with fixation of the graft to the epicardial myocardium. MICS CABG implies a beating-heart multi-vessel heart surgery performed through several small incisions under direct vision through an anterolateral mini-thoracotomy in the 4th-6th intercostal spaces. The patients can expect high quality of life resuming all everyday activities within a few weeks of their operation. NP were activated with NIR laser at 7 days after the intervention. Patients were treated with bolus of bivalirudin on the day of NP detonation.
Receives: Procedure: Transplantation of nanoparticles
Ferro groupActive comparator60 patients in Ferro group were managed with transplantation of iron-bearing nanoparticles (NP), particularly with intracoronary infusion of allogenous stem cells or CD68 targeted micro-bubbles pre-cultivated in the medium with iron-bearing NP. Cells and/ or micro-bubbles were infused with QCA- and IVUS-guidance to the target coronary artery via micro-catheter on the day of admission. The destruction of CD68 targeted micro-bubbles was obtained by using a Sonos 5500 machine with an S3 transducer operating in ultraharmonic mode (transmit, 1.3MHz/ receive, 3.6 MHz) with a mechanical index of 1.5 and a depth of 4 cm. The AXIOM Artis dBC (Siemens) magnetic navigation system was used for precise delivery of NP to the atheroma through two permanent computer-controlled external magnets generating a navigational magnetic field of 0.08 Tesla in any direction. NP were detonated with NIR laser under the protection of anti-platelet therapy.
Receives: Procedure: Transplantation of iron-bearing nanoparticles
Stenting controlOtherIn case of control group (stenting control), XIENCE V stent was implanted to 60 patients. Patients with a single de novo native coronary stenosis of less than 12 mm lesion length, more than 50% stenosis and reference diameter of 3.0 mm as assessed by online QCA were stented by a single stent of 3.0 x 18 mm. The procedure of implantation had to be performed according to common interventional practices including the administration of intracoronary nitroglycerine 0.2 mg of glycerol trinitrate or isosorbide dinitrate and intra-arterial heparin (50-100 U/kg body weight). Predilation with a conventional balloon catheter was recommended before DES deployment according to the manufacturer's recommendation. The protocol recommended the study stent should cover 2 mm of non-diseased tissue on either side of the target lesion. Postdilatation was allowed with a balloon that was shorter than was the study device.
Receives: Device: Stenting

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total Atheroma Volume

    Total atheroma volume (TAV, plaque-media volume, mm3) at 12 months. Quantitative coronary angiography (QCA) and Intravascular Ultrasound (IVUS) were performed pre-, post-procedure and at 12-month follow-up after a bolus infusion of i.c. nitrate. QCA was undergone with the CAAS II analysis system (Pie Medical B.V., Maastricht, The Netherlands) with analysis of different QCA parameters such as minimal lumen diameter, maximum lumen diameter, reference diameter, diameter stenosis, lesion length, percent atheroma volume (PAV), total atheroma volume (TAV), and lumen volume.

    Measured: at 12-month follow-up

  2. MACE (Major Adverse Cardiovascular Events)-Free Survival

    MACE (major adverse cardiovascular events)-free survival reflects per cent of survived patients without MACE. An amendment to the protocol was approved on August 29th 2012 with a decision to extend a 1-year study for another 4 years with the assessment of the 5-year clinical outcomes both retro- and prospectively.

    Measured: at 60 months follow-up

Secondary outcomes (16)
  1. Per Cent of Fibro-fatty Component

    IVUS (intravascular ultrasound) and IVUS-VH (virtual histology) images were acquired simultaneously with a phased array 20 MHz intravascular ultrasound catheter EagleEye (Volcano Co., Rancho Cordova, CA, USA) with motorized pull-back at a constant speed of 0.5 mm/s. Four tissue components (necrotic core - red; dense calcium - white; fibrous - green; and fibro-fatty - light green or yellow) were identified with autoregressive classification systems. For each cross section stent struts were detected as areas of apparent dense calcium and necrotic core. All IVUS analysis was performed offline by a CoreLab of the Ural Institute of Cardiology.

    Measured: at 12-month follow-up

  2. Event Free Survival

    The Kaplan-Meier analysis of the cardiac event-free survival (failure-free survival). The end point in this study was cardiac event-free survival during follow-up, starting at randomization. Cardiac events included cardiac death, myocardial infarction and unintended revascularization. Cardiac death was defined as sudden death, death after the onset of symptoms suggestive of cardiac ischemia and death due to heart failure. Noncardiac death was defined as death due to all other causes. Myocardial infarction was defined as an increase in cardiac enzymes or new pathologic Q-waves on the ECG, or both. Unintended revascularization was defined as PTCA or CABG performed due to worsening of the patient's clinical condition, rather than the PTCA or CABG assigned by the revascularization team when patient management was determined.

    Measured: at 12-month follow-up

  3. Restenosis Rate

    Restenosis (stenosis>50%) rate

    Measured: at 12-month follow-up

  4. Late Definite Thrombosis

    Late definite thrombosis rate

    Measured: at 12-month follow-up

  5. Coronary Vasomotion - Mean Lumen Diameter After Infusion of Acetylcholine 10-6 M

    Coronary vasomotion was assessed with QCA. End-diastolic images of coronary arteries were evaluated at baseline, after intravascular infusion of acetylcholine (through a microcatheter at increasing doses up to 10-8, 10-7, 10-6 M with a washout period of at least five minutes between each dose), and after nitroglycerine application following acetylcholine (100 µg orally). In all patients, measurements were performed in two segments on site of intervention while 960 seconds. The artery diameter was calibrated against the contrast-filled tip of the catheter. Vasoconstriction to acetylcholine was defined as a 3% change of the mean lumen diameter after infusion of the maximal dose of acetylcholine. An investigator blinded to treatment group performed all measurements.

    Measured: at 12-month follow-up

  6. Per Cent Atheroma Volume

    Per cent atheroma volume (PAV, plaque burden, %). Quantitative coronary angiography (QCA) and Intravascular Ultrasound (IVUS) were performed pre-, post-procedure and at 12-month follow-up after a bolus infusion of i.c. nitrate. QCA was undergone with the CAAS II analysis system (Pie Medical B.V., Maastricht, The Netherlands) with analysis of different QCA parameters such as minimal lumen diameter, maximum lumen diameter, reference diameter, diameter stenosis, lesion length, percent atheroma volume (PAV), total atheroma volume (TAV), and lumen volume.

    Measured: at 12-month follow-up

  7. Target Lesion Revascularization

    Target lesion revascularization, per cent

    Measured: at 12-month follow-up

  8. Per Cent of Fibrous Component

    IVUS (intravascular ultrasound) and IVUS-VH (virtual histology) images were acquired simultaneously with a phased array 20 MHz intravascular ultrasound catheter EagleEye (Volcano Co., Rancho Cordova, CA, USA) with motorized pull-back at a constant speed of 0.5 mm/s. Four tissue components (necrotic core - red; dense calcium - white; fibrous - green; and fibro-fatty - light green or yellow) were identified with autoregressive classification systems. For each cross section stent struts were detected as areas of apparent dense calcium and necrotic core. All IVUS analysis was performed offline by a CoreLab of the Ural Institute of Cardiology.

    Measured: at 12-month follow-up

  9. Per Cent of Necrotic Core

    IVUS (intravascular ultrasound) and IVUS-VH (virtual histology) images were acquired simultaneously with a phased array 20 MHz intravascular ultrasound catheter EagleEye (Volcano Co., Rancho Cordova, CA, USA) with motorized pull-back at a constant speed of 0.5 mm/s. Four tissue components (necrotic core - red; dense calcium - white; fibrous - green; and fibro-fatty - light green or yellow) were identified with autoregressive classification systems. For each cross section stent struts were detected as areas of apparent dense calcium and necrotic core. All IVUS analysis was performed offline by a CoreLab of the Ural Institute of Cardiology.

    Measured: at 12-month follow-up

  10. Per Cent of Calcium

    IVUS (intravascular ultrasound) and IVUS-VH (virtual histology) images were acquired simultaneously with a phased array 20 MHz intravascular ultrasound catheter EagleEye (Volcano Co., Rancho Cordova, CA, USA) with motorized pull-back at a constant speed of 0.5 mm/s. Four tissue components (necrotic core - red; dense calcium - white; fibrous - green; and fibro-fatty - light green or yellow) were identified with autoregressive classification systems. For each cross section stent struts were detected as areas of apparent dense calcium and necrotic core. All IVUS analysis was performed offline by a CoreLab of the Ural Institute of Cardiology.

    Measured: at 12-month follow-up

  11. Minimal Lumen Diameter

    Minimal lumen diameter (MLD, mm)

    Measured: at 12-month follow-up

  12. MACE

    MACE includes per cent of patients with cardiac death. STEMI (ST-elevation myocardial infarction), non-STEMI, and TLR (target lesion revascularization). An amendment to the protocol was approved on August 29th 2012 with a decision to extend a 1-year study for another 4 years with the assessment of the 5-year clinical outcomes both retro- and prospectively.

    Measured: at 60 months follow-up

  13. Cardiac Death

    Cardiac death includes per cent of patients passed away due to any cardiac death. An amendment to the protocol was approved on August 29th 2012 with a decision to extend a 1-year study for another 4 years with the assessment of the 5-year clinical outcomes both retro- and prospectively.

    Measured: at 60 months follow-up

  14. TLR (Target Lesion Revascularization)

    TLR (target lesion revascularization) reflects per cent of patients with TLR. An amendment to the protocol was approved on August 29th 2012 with a decision to extend a 1-year study for another 4 years with the assessment of the 5-year clinical outcomes both retro- and prospectively.

    Measured: at 60 months follow-up

  15. TVR (Target Vessel Revascularization)

    TVR (target vessel revascularization) reflects per cent of patients with TVR. An amendment to the protocol was approved on August 29th 2012 with a decision to extend a 1-year study for another 4 years with the assessment of the 5-year clinical outcomes both retro- and prospectively.

    Measured: at 60 months follow-up

  16. Mean Number of Membrane Defects on Membrane of Red Blood Cells

    Mean number of membrane defects on membrane of red blood cells calculated with atomic force microscopy (AFM) in random patients. An amendment to the protocol was approved on August 29th 2012 with a decision to extend a 1-year study for another 4 years with the assessment of the 5-year clinical outcomes both retro- and prospectively.

    Measured: at 60 months follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jan 2011 (estimated)
  2. Study start1 Apr 2007
  3. Primary completion1 Apr 2009
  4. Study completion1 Aug 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
180 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01270139
Sponsor's protocol ID
NANOM-FIM
Acronym
NANOM-FIM
Status last verified
Feb 2021
First submitted
30 Dec 2010
Last updated
17 Mar 2021
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The raw data will be partially shared (a Protocol for NANOM-FIM trial and related DREAM project; raw data with atomic force microscopy and scanning electron microscopy) in Mendeley Datasets and ResearchGate without any additional dissemination.

Publications

  • Kharlamov AN, Gabinsky JL. Plasmonic photothermic and stem cell therapy of atherosclerotic plaque as a novel nanotool for angioplasty and artery remodeling. Rejuvenation Res. 2012 Apr;15(2):222-30. doi: 10.1089/rej.2011.1305.

    PubMed 22533437
  • Kharlamov AN. Plasmonic photothermal therapy for atheroregression below Glagov threshold. Future Cardiol. 2013 May;9(3):405-25. doi: 10.2217/fca.13.16.

    PubMed 23668744
  • Kharlamov AN. Cardiovascular burden and percutaneous interventions in Russian Federation: systematic epidemiological update. Cardiovasc Diagn Ther. 2017 Feb;7(1):60-84. doi: 10.21037/cdt.2016.08.10.

    PubMed 28164014
  • Kharlamov AN. Glimpse into the Future of Nanotheranostic Strategies for Regression of Atherosclerosis through the Prism of Systems Biomedicine: Systematic Review of Innovations from Multifunctional Nanoformulations to Devices on Chip. Current Nanomedicine 6(3): 186-218, 2016. doi: 10.2174/2468187306666161121142756.

  • Kharlamov AN, Zubarev IV, Shishkina EV, Shur VY. Nanoparticles for treatment of atherosclerosis: challenges of plasmonic photothermal therapy in translational studies. Future Cardiol. 2018 Mar;14(2):109-114. doi: 10.2217/fca-2017-0051. Epub 2018 Jan 16. No abstract available.

    PubMed 29336170
  • Kharlamov AN, Tyurnina AE, Veselova VS, Kovtun OP, Shur VY, Gabinsky JL. Silica-gold nanoparticles for atheroprotective management of plaques: results of the NANOM-FIM trial. Nanoscale. 2015 May 7;7(17):8003-15. doi: 10.1039/c5nr01050k.

    PubMed 25864858
  • Kharlamov AN, Feinstein JA, Cramer JA, Boothroyd JA, Shishkina EV, Shur V. Plasmonic photothermal therapy of atherosclerosis with nanoparticles: long-term outcomes and safety in NANOM-FIM trial. Future Cardiol. 2017 Jul;13(4):345-363. doi: 10.2217/fca-2017-0009. Epub 2017 Jun 23.

    PubMed 28644056

Questions about this trial

What is this clinical trial studying?

A study testing Transplantation of nanoparticles, Transplantation of iron-bearing nanoparticles and Stenting in people with Stable Angina and Heart Failure, run by Ural State Medical University at 4 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Russia, Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Aug 2012). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total Atheroma Volume (time frame: at 12-month follow-up). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01270139, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in